Marketer takes helm of Sanofi vaccines division

Share this article:
Wayne Pisano
Wayne Pisano

Sanofi Pasteur named Wayne Pisano president and CEO, replacing David Williams, who is retiring. He reports to Sanofi Aventis CEO Gerard Le Fur.

Pisano was previously SVP, global commercial operations and corporate strategy, tasked with directing the development and implementation of the company's commercial strategy.

He joined the company from Novartis as VP, US marketing in 1997 and the following year was promoted to SVP marketing and sales. In that role, he orchestrated a reorganization of the department and is credited with helping fuel a 180% jump in sales over his five years as the firm's top marketing exec.

He went on to serve as EVP, Sanofi Pasteur North America and SVP, global commercial operations, helping to establish the market positions of key products such as Fluzone, IPOL and Menactra and overseeing the firm's joint venture with Merck, Sanofi Pasteur MSD.

The firm won FDA approval of its H5N1 vaccine in April. Sanofi Pasteur products include Fluzone, Menactra, ActHIB, Adacel and Pentacel. Agencies include Saatchi & Saatchi Innovations, Integrated Communications, Deutsch and Publicis PR.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...